patient safety.

Extractables are chemical entities that can be extracted from packaging components during laboratory testing under laboratory conditions using solvents and elevated temperatures. They provide information about the potential chemical profile of the materials used in packaging. On the other hand, leachables are compounds that can migrate into the drug product from the packaging under normal storage and use conditions. This migration can be influenced by the nature of the drug product, storage conditions, and packaging material characteristics.

Understanding E and L is vital for several reasons:

• Ensures patient safety by assessing potential toxicants in drug formulations.
• Aligns with regulatory requirements for drug approval and marketing.
• Reinforces the integrity and efficacy of biologics during their shelf life.

Regulatory Landscape: FDA, EMA, and ICH Guidelines for E and L

Compliance with regulatory guidelines is essential for ensuring that packaging materials do not pose a risk to the drug product’s safety and efficacy. The following are key regulations and guidelines by major authorities:

• FDA: The FDA’s guidance documents for E and L studies are crucial for assessing potential chemical contaminants from packaging. The Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics provides recommendations on testing for extractables and leachables.
• EMA: The European Medicines Agency provides guidelines aligning with ICH principles, focusing on the necessary evaluations for packaging materials in terms of E and L. Reference the EMA draft guidelines for detailed compliance requirements.
• ICH: ICH guidelines, particularly ICH Q8 and ICH Q9, emphasize Quality by Design principles, which play a critical role in evaluating risks associated with E and L, promoting the assessment of packaging systems as part of the integrated product quality system.

Step 1: Define the Scope of Auditing Packaging Suppliers

The initial step in auditing packaging suppliers involves defining the scope of the audit. This stage sets the foundation for subsequent assessments and should encompass both E and L evaluations as well as an overview of the supplier’s quality system.

Consider the following key elements when defining the scope:

• Product Type: Identify the types of biologics the packaging supplier will work with. Different biologics may require different types of packaging materials and testing protocols.
• Regulatory Requirements: Align your audit scope with the pertinent regulatory requirements focusing on E and L evaluations. Understand the specific regulations applicable to your product’s geographic market, whether it be the US, UK, or EU.
• Risk Assessment: Conduct an initial risk assessment to understand the potential implications of E and L on product safety based on the packaging choice.

With a well-defined scope in mind, you can move to the next phase of the audit process.

Step 2: Assess the Supplier’s Quality Management System

The robustness of a supplier’s quality management system (QMS) is crucial for ensuring compliance with good manufacturing practices (GMP) in the context of biologics.

Evaluate the following aspects of the supplier’s QMS:

• Quality Policy: Review the supplier’s quality policy to understand their commitment to quality.
• Documented Procedures: Ensure they have documented procedures in place for E and L studies and the handling of deviations. This is essential for maintaining compliance.
• Training Records: Verify that staff members involved in the packaging process are adequately trained and that these training sessions are documented.
• Quality Control Processes: Review their quality control processes, including their methodologies for validating packaging materials and assessing E and L.
• Change Control Procedures: Confirm that the supplier has established change control procedures that include assessing the impact of any changes on E and L results.

By assessing the QMS, the auditing team can identify areas that require improvement and ensure that the supplier adheres to necessary quality standards.

Step 3: Evaluate Packaging Materials and Suppliers’ E and L Studies

A critical component of the audit involves a thorough evaluation of the packaging materials used, as well as the results of the suppliers’ E and L studies.

Consider the following during the evaluation:

• Material Selection: Ensure that the supplier uses materials suitable for the specific biologics you are working with. This may necessitate reviewing supplier specifications and their rationale for material choices.
• Performing E and L Studies: Evaluate the methodologies used for conducting E and L studies. Check whether they have employed best practices, including solvent selection, time, and temperature profiles.
• Test Results Review: Examine the results from E and L studies. Pay particular attention to potential contaminants identified and any assessments made regarding their toxicity.
• Comparative Data: If possible, request comparative data from past E and L studies to gauge consistency in performance and compliance.

This step will allow you to ascertain the reliability of the packaging supplier’s E and L assessment protocols and whether their materials meet the necessary safety profiles.

Step 4: Conduct Supplier Interviews and On-Site Visits

Interviews and on-site visits can provide valuable insights that go beyond documentation. Engaging directly with the supplier fosters a clearer understanding of packaging processes and quality management.

During interviews, focus on the following:

• Supplier’s Expertise: Inquire about the supplier’s experience with biologics packaging and their understanding of E and L concerns.
• R&D Capabilities: Understand their research and development (R&D) capabilities, especially concerning innovations in packaging materials and processes designed to minimize E and L.
• Collaboration and Communication: Evaluate how well the supplier collaborates and communicates with your organization regarding packaging decisions and quality improvements.

On-site visits are particularly valuable in observing the operational quality and practices undertaken by the supplier involving their production processes along with their compliance levels.

Step 5: Review Toxicological Assessments of Leachables

One of the most critical facets of E and L studies is the toxicological assessment of leachables. The aim is to determine the safety of any substances migrating into the biologic product during storage or use.

Consider the following during your review:

• Toxicological Reports: Review detailed toxicological assessments produced by the supplier, ensuring they comply with recognized standards and guidelines.
• Assessment Methodologies: Understand the methodologies used to assess leachables, including analytical techniques and interpretations used for safety evaluations.
• Risk Characterization: Evaluate how risks associated with leachables are characterized, including uncertainty factors, dose-response information, and potential exposure assessment.

It’s important that the toxicological assessment aligns with the overall risk management approach of your quality system.

Step 6: Document Findings and Recommend Improvements

Upon concluding the audit, comprehensive documentation of findings is crucial. Summarizing strengths and weaknesses, as well as recommendations for improvement, will assist in mitigating risks associated with E and L.

In your documentation, include:

• Audit Summary: Provide an overview of the audit, detailing what was assessed and the outcome.
• Identified Risks: Highlight any significant risks associated with the supplier’s E and L practices or QMS.
• Actionable Recommendations: Offer specific recommendations for improvement that the supplier can implement to enhance compliance and safety standards.
• Follow-Up Procedures: Outline any needed follow-up actions or meetings to assess the implementation of recommendations.

Conclusion

In summary, auditing packaging suppliers for E and L requires a systematic approach and attention to detail. By following the outlined steps — from defining the audit’s scope to documenting findings and recommending improvements — CMC leads and packaging development teams can ensure that suppliers adhere to necessary quality standards that align with global regulatory requirements.

Thorough audits of packaging suppliers not only enhance compliance with extractables leachables biologics guidelines but also contribute significantly to the safety and efficacy of the biologic products, thereby ensuring better patient outcomes and trust in the products developed.